{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Qualls AE"],"funding":["National Institute of Allergy and Infectious Diseases","BLRD VA","Biomedical Advanced Research and Development Authority","NIDDK NIH HHS","NIDA NIH HHS","NIAID NIH HHS","NIH Clinical Center","NIH HHS","NIGMS NIH HHS","National Science Foundation"],"pagination":["e191314"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12306582"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(13)"],"pubmed_abstract":["CD16A is an activating Fc receptor on NK cells that mediates antibody-dependent cellular cytotoxicity (ADCC), a key mechanism in antiviral immunity. However, the role of NK cell-mediated ADCC in SARS-CoV-2 infection remains unclear, particularly whether it limits viral spread and disease severity or contributes to the immunopathogenesis of COVID-19. We hypothesized that the high-affinity CD16AV176 polymorphism influences these outcomes. Using an in vitro reporter system, we demonstrated that CD16AV176 is a more potent and sensitive activator than the common CD16AF176 allele. To assess its clinical relevance, we analyzed 1,027 patients hospitalized with COVID-19 from the Immunophenotyping Assessment in a COVID-19 cohort (IMPACC), a comprehensive longitudinal dataset with extensive transcrip"],"journal":["JCI insight"],"pubmed_title":["High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19."],"pmcid":["PMC12306582"],"funding_grant_id":["R01AI145835-01A1S1","R01 AI104870","N01 AI025482","U19 AI062629","4U19AI090023-11","U54 AI142766","U19 AI118610","5U19AI062629-17","5U19AI118608-04","5T3","3U19AI089992-09","R01 AI122220","U19 AI128910","U19 AI128913","5R01AI104870-07","4U19AI118610-06","S10 OD026940","5U19AI125357-05","R01 AI135803","P30 DK063720","R56 AI146581","3U19AI077439-13","HHSO10201600031C","3U19AI128913-03","N01 AI025496","5U54AI142766-03","AI146581","5U19AI128913-03","T32 DA018926","U19 AI090023","5U19AI057229-17","DMS2310836","R01AI122220","5U19AI128910-04","U19 AI077439","5R01AI135803-03","I01 BX005023","R01 AI145835","U19 AI118608","U19 AI057229","U19 AI125357","U19AI128913-04S1","U19 AI089992","3U19AI1289130","R01 AI146581","T32 GM141323"],"pubmed_authors":["Duchen D","Ehrlich LI","Peters B","Higuita NIA","Langelier CR","Simon V","Kheradmand F","Augustine AD","Rouphael N","Maecker HT","Pickering H","McComsey GA","Sekaly RP","Corry DB","Davis MM","Reed EF","Su Y","Metcalf JP","Haddad EK","Diray-Arce J","Ozonoff A","Melamed E","Cairns CB","Kim-Schulze S","Baden LR","Brakenridge SC","Pulendran B","Chen E","Hough CL","Nadeau KC","Montgomery RR","Kraft M","Bime C","Levy O","IMPACC Network","Calabrese DR","Wells JA","Goldman JD","Lanier LL","Hafler DA","Schaenmann J","Calfee CS","Heath JR","Krammer F","Aguilar OA","Lim SA","Erle DJ","Kleinstein SH","Tsao T","Shaw AC","Messer WB","Lui I","Qualls AE","Atkinson MA","Fernandez-Sesma A","Becker PM"],"additional_accession":[]},"is_claimable":false,"name":"High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19.","description":"CD16A is an activating Fc receptor on NK cells that mediates antibody-dependent cellular cytotoxicity (ADCC), a key mechanism in antiviral immunity. However, the role of NK cell-mediated ADCC in SARS-CoV-2 infection remains unclear, particularly whether it limits viral spread and disease severity or contributes to the immunopathogenesis of COVID-19. We hypothesized that the high-affinity CD16AV176 polymorphism influences these outcomes. Using an in vitro reporter system, we demonstrated that CD16AV176 is a more potent and sensitive activator than the common CD16AF176 allele. To assess its clinical relevance, we analyzed 1,027 patients hospitalized with COVID-19 from the Immunophenotyping Assessment in a COVID-19 cohort (IMPACC), a comprehensive longitudinal dataset with extensive transcrip","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-03-27T16:51:53.661Z","creation":"2025-08-27T03:11:07.142Z"},"accession":"S-EPMC12306582","cross_references":{"pubmed":["40402577"],"doi":["10.1172/jci.insight.191314"]}}